Current Agreements: The Definitive Life Sciences Deal Intelligence Database

Empowering Business Decisions with Unparalleled Access to Licensing, M&A, and Partnership Agreements

Why Choose Current Agreements?

Our platform offers exclusive access to real-world contract terms, financial structures, and strategic deal components, allowing you to:

• Benchmark Market Standards – Gain critical insights into industry-specific payment terms, royalty structures, and licensing fees.
• Analyze Competitive Strategies – Track deal trends and strategic alliances across biopharma, medtech, and diagnostics sectors.
• Identify New Opportunities – Discover companies actively engaging in licensing, M&A, and R&D collaborations within your area of interest.
• Enhance Negotiation Power – Leverage precise deal data to support your licensing and investment strategies.
• Stay Ahead of Industry Trends – Monitor evolving business models, deal structures, and emerging partnerships in the life sciences ecosystem.

Who Benefits from Current Agreements?

Our platform is an indispensable resource for professionals involved in business strategy, licensing, and corporate development, including:

• C-Level Executives – Make informed strategic decisions based on comprehensive market intelligence.
• Business Development & Licensing Teams – Identify potential partners and benchmark deal terms for negotiations.
• Technology Transfer & Intellectual Property Managers – Secure advantageous licensing agreements by understanding standard industry practices.
• Investment Analysts & Financial Advisors – Evaluate the financial viability and investment potential of emerging partnerships.
• Legal & Compliance Experts – Access detailed contract provisions and regulatory filings to support due diligence efforts.
• Consultants & Market Researchers – Gain deep insights into the competitive landscape and deal trends shaping the industry.

What Sets Current Agreements Apart?

Each deal record within Current Agreements is structured to provide a complete and transparent view of the transaction, with verified source material including press releases, SEC filings, company disclosures, and full contract documents.

Every deal profile includes:

• Executive Summary – An overview detailing key parties, transaction type, and strategic significance.
• Term Sheet – A structured summary outlining critical deal components, including financial terms and obligations.
• Detailed Categorization – Indexed across multiple parameters such as industry sector, therapeutic focus, geographic region, and development stage.
• Financial Breakdown – Comprehensive disclosure of upfront payments, milestones, royalties, and revenue-sharing agreements.
• Regulatory Filings & Contract Documents – Access official regulatory submissions and, where available, full contract texts for an in-depth legal perspective.

A Trusted Source for Verified, High-Value Market Intelligence

Our commitment to accuracy, depth, and transparency ensures that every data point in Current Agreements is meticulously sourced and structured for optimal usability.

Whether you are conducting competitive analysis, pursuing licensing deals, or advising on corporate transactions, Current Agreements provides the critical intelligence necessary to drive success in the rapidly evolving life sciences industry.

Twelve month subscription to our online deals and alliances database. 

Access runs for twelve months and pricing starts from just $5995.

About Current Partnering

A definitive, evidence-based approach to dealmaking intelligence

Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.

Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.

All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.

Our methodology

Built on a continuously updated proprietary database

All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.

Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.

Comprehensive and verifiable data sourcing

Deal data is sourced from publicly available industry disclosures, including:

• Company press releases and announcements
• SEC filings and equivalent regulatory disclosures
• Company and investor presentations
• Conference materials and company websites

All sources are captured and referenced, enabling full transparency and user verification.

Broad coverage across deal types and structures

Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:

• Licensing and co-development
• Research and collaborative R&D
• Manufacturing, supply, and distribution
• Commercialisation and co-promotion
• Equity investments, joint ventures, and asset transactions
• Options, royalties, and financing agreements

This breadth ensures a complete view of how partnerships are structured across the life sciences sector.

Structured, standardised analysis

Every deal is analysed using a consistent framework, capturing (where disclosed):

• Financial terms — including upfront payments, milestones, and royalties
• Rights allocation — development, manufacturing, and commercialization responsibilities
• Deal structure — exclusivity, territorial scope, and agreement type
• Contractual provisions — clauses defining risk, control, and value-sharing

Each deal record is fully categorised, including data fields such as:

• Therapy area and technology type
• Stage of development
• Asset type and deal components
• Geographic scope and exclusivity
• Source documentation, including press releases and SEC filings

Financial normalisation for comparability

All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.

Contract-level insight

Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.

This enables users to understand:

• How financial mechanisms are defined and triggered
• How responsibilities are operationalised between parties
• How flexibility, risk, and control are allocated within agreements

Designed for real-world application

Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:

• Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
• Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
• Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight

Common use cases include:

• Benchmarking comparable transactions
• Supporting valuation and deal structuring
• Preparing for negotiations
• Evaluating potential partners
• Informing internal strategy with real-world evidence

A trusted industry reference

With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.

By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.